SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of August, 2015
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address
of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only permits
the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82 -
EXHIBIT
NUMBER |
|
DESCRIPTION |
| |
|
|
| 99.1 |
|
News
Release Dated August 26, 2015 - Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Non-Small Cell Lung
Cancer Study |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Oncolytics Biotech Inc.
(Registrant) |
| |
|
|
| |
|
|
| Date:
August 26, 2015 |
By: |
/s/ Kirk Look |
| |
|
Kirk Look |
| |
|
Chief Financial Officer |
Exhibit 99.1
Oncolytics Biotech® Inc. Announces Completion of Enrollment
in Randomized Phase II Non-Small Cell Lung Cancer Study
CALGARY, Aug. 26, 2015 /CNW/ - Oncolytics Biotech® Inc.
("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that enrollment has been completed in a randomized Phase II study
of REOLYSIN® in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC")
(IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University
in Kingston, Ontario.
"Non-small cell lung cancer continues
to present a significant health risk for patients," said Dr. Brad Thompson, President and CEO of Oncolytics. "We would
like to thank our colleagues at the NCIC CTG for completing enrolment in this study."
The study is an open-label, randomized,
non-blinded, Phase II clinical study of REOLYSIN® as a treatment for advanced or metastatic non-small cell lung
cancer patients who have received previous chemotherapy. A total of 166 patients were enrolled. Patients with squamous cell histology
were randomized to receive either REOLYSIN® given in combination with docetaxel (test arm) or docetaxel alone (control
arm), while patients with non-squamous cell histology were randomized to receive either REOLYSIN® given in combination
with pemetrexed (test arm) or pemetrexed alone (control arm).
The primary objective of the trial is
to evaluate the effect of REOLYSIN® in combination with standard salvage chemotherapy on the progression free survival
of patients with advanced or metastatic non-small cell lung cancer. The secondary objectives are to determine the tolerability
and toxicity of the therapeutic combination; to investigate additional potential measures of efficacy, including progression rates
at three months, objective response rate and overall survival; and to explore potential molecular factors predictive of response.
Although accrual is complete, patient
follow-up will continue until planned analyses have been conducted.
About NSCLC
The Canadian Cancer Society estimates that 26,600 Canadians will be diagnosed with lung cancer and that 20,900 Canadians are expected
to die from the disease in 2015. The American Cancer Society estimates that 221,200 new cases of lung cancer will be diagnosed
in the United States and that 158,040 Americans are expected to die from the disease in 2015. Approximately 80% of all lung cancer
cases are of the non-small cell type.
About the NCIC Clinical Trials
Group at Queen's University
The NCIC Clinical Trials Group (NCIC CTG) is a cancer clinical trials cooperative group that conducts Phase I-III trials testing
anti-cancer and supportive therapies across Canada and internationally. It is a national research program of the Canadian
Cancer Society. The NCIC CTG's Central Operations and Statistics Office is located at Queen's University in Kingston, Ontario,
Canada.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking
statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended,
and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical
facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will
or may occur in the future, including such things as, the Company's expectations related to Phase II NSCLC trial sponsored by the
NCIC CTG, the Company's belief as to the potential of REOLYSIN® as a cancer therapeutic, and other
such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties,
which could cause the Company's actual results to differ materially from those in the forward-looking statements and forward-looking
information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment
numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy
of REOLYSIN® as a cancer treatment, the tolerability of REOLYSIN® outside a controlled test, the
success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN®,
uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors
should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking statements and forward-looking information. Investors are cautioned
against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to
update these forward-looking statements and forward-looking information, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
%CIK: 0001129928
For further information: TMX Equicom, Nick Hurst, 300 5th
Ave. SW, 10th Floor, Calgary, Alberta T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@tmxequicom.com; TMX Equicom, Michael
Moore, San Diego, CA, Tel: 858.886.7813, mmoore@tmxequicom.com; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd Floor,
New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 26-AUG-15